The Trajectory of Blood Pressure During Pregnancy in Assisted Reproductive Females

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The incidence of gestational hypertension and preeclampsia in the assisted reproductive technology population during pregnancy was significantly higher than that in the general normal pregnancy population. The use of assisted reproductive technology in this population due to infertility is often accompanied by many hypertension-related factors. We established a prospective cohort study based on assisted reproductive technology pregnancy population and natural pregnancy population. Through continuous monitoring of blood pressure changes and other risk factors during pregnancy in the two groups, we explored the trajectory trend and inflection point of assisted reproductive technology pregnancy population blood pressure during pregnancy. Through factor analysis, the risk factors of elevated blood pressure during pregnancy can be clearly identified, so as to carry out early intervention and strengthen the control of risk factors of elevated blood pressure in assisted reproductive technology population, in order to expect benign maternal and infant outcomes.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 20
Maximum Age: 45
Healthy Volunteers: f
View:

• Exposure group:

∙ Mother: Seen in the obstetrics department of our hospital and meet the following conditions at the same time:

⁃ Complete at least one cycle of IVF or ICSI, PGD or IVM treatment (including natural cycles);

⁃ Clinical pregnancy was obtained after treatment. Offspring: Offspring born after in vitro fertilization-embryo transfer technique.

‣ Non-exposed group:

∙ Mother: A mother who conceived naturally. Offspring: 1) Offspring born by natural pregnancy. 2) Offspring born from natural pregnancy of exposed mothers.

Locations
Other Locations
China
Cui linlin
RECRUITING
Jinan
Contact Information
Primary
Wenting Wang, M.D. Ph.D.
13188936075@163.com
+86 17660082326
Time Frame
Start Date: 2022-11-01
Estimated Completion Date: 2025-06-30
Participants
Target number of participants: 2000
Treatments
Natural pregnancy group
Assisted Reproductive Technology Group
Sponsors
Leads: The Second Hospital of Shandong University

This content was sourced from clinicaltrials.gov